monopar.jpg
Monopar Announces Plan to Advance Development of Novel Triage Test for Severe COVID-19 Utilizing its Patented Technology
12 août 2020 08h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced its plan to develop a test to potentially triage COVID-19 patients into those likely versus...
monopar.jpg
Monopar and NorthStar Partner with IsoTherapeutics for the Manufacturing of Potential Therapeutic for Severe COVID-19
10 août 2020 08h30 HE | Monopar Therapeutics Inc.
WILMETTE, Ill. and BELOIT, Wis. and ANGLETON, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Wilmette, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI),...
monopar.jpg
Monopar Therapeutics Reports Second Quarter 2020 Financial Results and Business Updates
06 août 2020 16h05 HE | Monopar Therapeutics Inc.
CHICAGO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary...
monopar.jpg
Monopar and NorthStar Announce Filing of Provisional Patent Protecting Development and Use of Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19 Through uPAR
30 juin 2020 08h25 HE | Monopar Therapeutics Inc.
CHICAGO and BELOIT, Wis., June 30, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today that a...
monopar.jpg
Monopar and NorthStar Join Forces to Develop Radio-Immuno-Therapeutics (RITs) Targeting Severe COVID-19
16 juin 2020 08h25 HE | Monopar Therapeutics Inc.
CHICAGO and BELOIT, Wis., June 16, 2020 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (Chicago, IL) and NorthStar Medical Radioisotopes, LLC (Beloit, WI) announced today a 50/50...
monopar.jpg
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Business Updates
27 mars 2020 09h15 HE | Monopar Therapeutics Inc.
Initial public offering on Nasdaq Capital Market in December 2019 Orphan Drug Designation from the European Commission for camsirubicin for the treatment of soft tissue sarcoma CHICAGO, March 27,...
monopar.jpg
Monopar Therapeutics Inc. Announces Closing of Initial Public Offering of Common Stock
23 déc. 2019 12h30 HE | Monopar Therapeutics Inc.
CHICAGO, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’...